Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2012

View Archived Issues

AEOL-10150 demonstrates neuroprotective effects in rat model

Computational model includes all molecular components and interactions of pathogen's life cycle

Phase I/II trial assesses ROSE-010 in IBS-C

Vivalis synthesizes new candidate hepatitis therapies

New colimycin biosynthesis genes patented

Zetonna launched in U.S.

Omeros discovers key proteins in MASP-2 program

Novel protein kinase inhibitors disclosed by Leo Pharma

Phase I ALS-2200 data disclosed

Chinese researchers present new candidate cancer drugs

Novel tubulin polymerization inhibitors patented by group in Taiwan

U.S. university patents novel mGlu5 receptor modulators

Torii Pharmaceutical launches new Mitizax trials in Japan

La Jolla Pharmaceutical gives update on GCS-100 plans

Transgene and Tasly Pharmaceutical form joint venture

APP gene variant linked to reduced cognitive decline

FDA accepts Zelrix NDA resubmission for filing

CytoDyn to acquire antibody inhibiting HIV entry

Oncobiologics to utilize Xoma antibody technology platform

Second phase of malaria grant awarded to PolyMedix

MolecularMD seeks approval for companion diagnostic test

GenSpera's lead product clear to advance to phase II testing

Clinical proof of concept demonstrated for SCY-635

Recruitment complete in pivotal CRUISE trials

EryDel product receives orphan drug status for ataxia telangiectasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...